Strategic Partnership Prospect is actively expanding via high-profile collaborations, including the May 2026 Merck partnership to offer end-to-end biopharma testing across the product lifecycle. Target account expansions with large biopharma and gene therapy players seeking integrated analytics and lifecycle testing.

Comprehensive Analytics ProtaGene offers integrated protein and gene analytics across biologics and cell/gene therapies, backed by a multi‑site footprint. Use cases include vector safety, integration site analysis, and bioinformatics—offer adjacent services or bundle analytics contracts for end-to-end coverage.

Leadership & Talent Senior leadership changes and executive appointments since 2022, including CEO and CCO hires, indicate a focus on strategic growth and client-facing expansion. Leverage relationships with decision-makers and align value proposition to governance and commercial growth objectives.

Global Footprint Four sites across Europe and North America enable nearshore and offshore testing capabilities with geographical flexibility. Position as a globally scalable CRO partner for multinational biopharma programs requiring synchronized analytics across regions.

Growth Signals Revenue in the mid tens of millions and a history of investing in new analyticalTech (e.g., Differential Scanning Calorimetry) signal continuous capability enhancement. Opportunities exist to upsell advanced analytics packages, ongoing monitoring, and expanded portfolio testing for late-stage development and GMP release testing.